Page 27 - Morphosys This News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys this. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys This Today - Breaking & Trending Today

MorphoSys AG (NASDAQ:MOR) Receives Consensus Rating of "Hold" from Analysts

Shares of MorphoSys AG (NASDAQ:MOR – Get Rating) have earned an average rating of “Hold” from the fourteen research firms that are covering the company, MarketBeat reports. Eleven investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokers […] ....

United States , Morgan Stanley , Berenberg Bank , Zacks Investment Research , Blackrock Inc , Alphacentric Advisors , Morphosys Company Profile Get Rating , Cubist Systematic Strategies , Get Rating , Investment Research , Systematic Strategies , Sys Company Profile , Nasdaq Mor ,

MorphoSys (NASDAQ:MOR) Price Target Cut to €40.00

MorphoSys (NASDAQ:MOR – Get Rating) had its target price lowered by analysts at Morgan Stanley from €50.00 ($54.95) to €40.00 ($43.96) in a research note issued to investors on Monday, The Fly reports. The brokerage currently has an “equal weight” rating on the stock. A number of other research analysts have also commented on the […] ....

United States , Morgan Stanley , Berenberg Bank , Zacks Investment Research , Deutsche Bank Aktiengesellschaft , Blackrock Inc , Alphacentric Advisors , Morphosys Company Profile Get Rating , Millennium Management , Get Rating , Bank Aktiengesellschaft , Investment Research , Bay Capital Management , Sys Company Profile , Nasdaq Mor , Lower Price Target ,

DGAP-News: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL Seite 1

22.03.2022 - DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL 22.03.2022 / 21:01 The issuer . Seite 1 ....

Switzerland General , Jonathan Dickinson , Mike Akimov , Incyte Europe , Head Of Global Drug Development , Incyte Announce Swissmedic Temporary Approval , Diffuse Largeb Cell , Executive Vice President , General Manager , Global Drug Development , Gap News ,

MorphoSys AG: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL

MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell LymphomaMinjuvi ....

Switzerland General , United Kingdom , United States , Julia Neugebauer , Mike Akimov , Incyte Europe , Myles Clouston , Nationaler Krebsbericht , Jeanette Bressi , Thomas Biegi , Jonathan Dickinson , Christine Chiou , Hematology Am Soc Hematol Educ Program , Practice Research Clinical Haematology , Us Communications , Head Of Global Drug Development , Xencor Inc , Drug Administration , Distribution Services , Exchange Commission , Public Affairs , Cancer Research United Kingdom , Kantar Market Research , Incyte Announce Swissmedic Temporary Approval , Refractory Diffuse Largeb Cell , Executive Vice President ,

MorphoSys (NASDAQ:MOR) Receives Buy Rating from JMP Securities

JMP Securities reiterated their buy rating on shares of MorphoSys (NASDAQ:MOR – Get Rating) in a report issued on Friday morning, MarketBeat Ratings reports. The brokerage currently has a $41.00 price target on the stock. MOR has been the subject of several other research reports. Zacks Investment Research raised MorphoSys from a sell rating to […] ....

Morgan Stanley , Goldman Sachs Group Inc , Morphosys Company Profile Get Rating , Zacks Investment Research , Quadrant Capital Group , Us Bancorp , Get Rating , Marketbeat Ratings , Investment Research , Capital Group , Goldman Sachs Group , Sachs Group , Sys Company Profile , Proprietary Development , Partnered Discovery , Nasdaq Mor , Reiterated Rating , Jmp Securities ,